BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kodensha Co Ltd
TSE:1948
|
JP |
|
Restar Holdings Corp
TSE:3156
|
JP |
|
R
|
RWE AG
OTC:RWNFF
|
DE |
BiVictriX Therapeutics PLC
Total Equity
BiVictriX Therapeutics PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Total Equity
£3.5m
|
CAGR 3-Years
270%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Equity
$610m
|
CAGR 3-Years
31%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Equity
£381m
|
CAGR 3-Years
11%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Equity
-$52.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Equity
£504m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Equity
£91.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
24%
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
See Also
What is BiVictriX Therapeutics PLC's Total Equity?
Total Equity
3.5m
GBP
Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Total Equity amounts to 3.5m GBP.
What is BiVictriX Therapeutics PLC's Total Equity growth rate?
Total Equity CAGR 3Y
270%
Over the last year, the Total Equity growth was -11%. The average annual Total Equity growth rates for BiVictriX Therapeutics PLC have been 270% over the past three years .
